Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00424554
Status:
COMPLETED
Last Update Posted:
2017-06-07
First Post:
2007-01-18
Brief Title:
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas P04602 AM1 Completed
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase II Trial to Evaluate the Effect of Low Dose Temozolomide TMZ for 2 Weeks on Brain Tumor O-6-methylguanine-DNA Methyltransferase MGMT Activity in Patients With Gliomas
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to assess the effect of a two-week pre-surgery treatment with low-dose temozolomide TMZ on brain tumor methylguanine-DNA deoxyribonucleic acid methyltransferase MGMT activity in patients with gliomas
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None